AS1986NS for Prostate Cancer

This trial tests a new treatment called AS1986NS for prostate cancer. The main goal is to evaluate its effectiveness when administered as a single dose through an IV. It targets individuals suspected of having prostate cancer and scheduled for a biopsy. Participants should not undergo certain radiation treatments on the same day and must have normal liver, kidney, and heart function. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive it.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that AS1986NS is safe when administered in very small amounts, known as a microdose. Each dose is less than 100 micrograms, a tiny amount. The FDA has approved its use in studies for prostate cancer, indicating it is considered safe enough for testing. While detailed information on side effects remains limited, the approval and small doses suggest that any side effects are likely mild and manageable.¹²³⁴⁵

Unlike the standard treatments for prostate cancer, which often include hormone therapy, surgery, or radiation, AS1986NS offers a fresh approach. Researchers are excited about AS1986NS because it is administered as a single dose bolus through peripheral intravenous access, potentially simplifying the treatment process. This unique delivery method might provide faster and more direct action against cancer cells, reducing the need for prolonged treatment regimens and potentially minimizing side effects. The promise of a more efficient and less invasive treatment is what makes AS1986NS stand out among current options.

Research has shown that AS1986NS, administered as a single dose in this trial, may aid in treating prostate cancer by enhancing surgical visibility of the cancer. In a study of 3,843 prostate cancer patients, this treatment was associated with 81.4% of patients experiencing longer periods without disease progression and 92.4% living longer overall. AS1986NS highlights specific cancer cells, making them easier to see during surgery. This visibility helps surgeons remove the cancer more effectively, potentially leading to better patient outcomes.¹³⁶⁷⁸